New Strategic Investment Set to Speed Up Growth for PCI
With this latest private transaction, Bain Capital, a private investment firm, joins PCI’s investor base of Kohlberg, Mubadala, and Partners Group, which are focused on supporting the company in its growth plans.
Integrated, end-to-end CDMO, PCI Pharma Services, has received a strategic investment to accelerate its growth trajectory, the company announced in a July 14, 2025 press release (1). Existing lead investor, Kohlberg, was joined by Bain Capital and supported by Mubadala Investment Company for this transaction, with Partners Group continuing to provide a minority investment as well.
“PCI has embarked on a purposeful journey to transform itself into a global CDMO by executing its successful growth strategy, providing industry-leading customer experience, and offering innovative and integrated supply chain solutions. I am grateful for the ongoing support of our existing investors and enthusiastically welcome Bain Capital and their deep, global healthcare and life science capabilities and expertise,” said Salim Haffar, CEO of PCI, in a company press release (1). “Together we will grow PCI’s commercial, clinical trial services, and development and manufacturing businesses to meet the future demands of our biopharmaceutical customers.”
The investors will work with PCI’s management team to progress the company’s growth, build on its customer service experience, and further enable PCI customers to bring their biopharmaceutical therapies to market. Primary areas of focus for PCI will be organic and inorganic growth initiatives, such as expanding its suite of services and geographic reach. Future investments will incorporate the expansion of existing sterile fill/finish capacity for injectables and highly potent and specialized products.
“PCI’s world-class management team, combined with the support of experienced industry investors, has proven to be a very successful formula,” commented Matt Jennings, Chairman of PCI and an Operating Partner of Kohlberg, in the press release (1). “We are delighted for Bain Capital to join PCI’s investor base, yielding an optimal combination aligned to support Salim and the management team to execute on their growth ambitions and value creation pathways.”
“Anchored by an innovative, advanced platform that is consistently growing and setting new standards for the industry, PCI Pharma has built a well-deserved reputation as a differentiated partner to leading biopharma companies, ensuring critical therapies reach patients safely and efficiently,” remarked Devin O’Reilly, Partner at Bain Capital, in the press release (1). “We look forward to working alongside Kohlberg to build on this strong foundation.”
Kohlberg and Mubadala initially invested in PCI in 2020, purchasing the majority equity stake in the company from Partners Group (2). The purchase was closed in December 2020 (2).
Financial transaction terms of the initial purchase by Kohlberg and Mubadala in 2020 and the latest strategic investment were not disclosed.
Reference
PCI Pharma Services. PCI Pharma Services Enters Next Phase of Growth with Strategic Investment from Bain Capital, Kohlberg, and Mubadala. Press Release, July 14, 2025.
PCI Pharma Services. Kohlberg and Mubdala Sign a Definitive Agreement to Acquire Majority Stake in PCI Pharma Services. Press Release, Aug. 24, 2020.
PCI Pharma Services. PCI Pharma Services Announces the Closing of the Majority Stake Acquisition by Kohlberg and Mubadala. Press Release, Dec. 1, 2020.